We provide you with a range of benefits and services, including counselling, exercise classes, social events to help you stay mentally and physically fit.
Boehringer Ingelheim Social Engagements Contributes to company commitment to impact 50 million people in vulnerable communities by 2030 through supporting social entrepreneurs and innovative solutions
Bronchiectasis is a chronically progressive pulmonary disease. Boehringer Ingelheim investigates a potential new treatment option in two Phase II trials.
Manami Tsutsumi, Senior Associate Director in Research & Development describes what it's like working on the cutting edge of pharmaceutical development.
Boehringer Ingelheim and the IoPPN at King’s College London partner to progress new therapeutic concepts in major depressive disorder and schizophrenia